JPRN-UMIN000032423已完成2 期
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer - Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 80years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •(1) Cancer patients with a duplication of activity (2) Patients with severe or uncontrollable diabetes (3) Serious medical complications (uncontrollable collagen disease, heart disease, interstitial pneumonia, liver cirrhosis, etc.) (4) Mental diseases which prevent from registration of this trial (5) History of pelvic radiation therapy (6) History of pelvic surgery (7) History of prostate surgery including TUR-P and HIFU (8) History of chemotherapy for prostate cancer (9) Patients with inflammatory bowel disease (10) Patients treated with anticoagulant (11) IPSS => 20 (12) Persons who are judged inappropriate by the researcher
研究者
相似试验
进行中（未招募）
1 期
A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.ocally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2016-000877-19-GBStarpharma Pty Ltd.65
进行中（未招募）
1 期
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.EUCTR2019-001318-40-GBStarpharma Pty Ltd149
进行中（未招募）
1 期
A phase 1/2 study in which, CTX-SPL9111, the trial medication will be administered to evaluate the safety, tolerability, pharmacokinetics (distribution of CTX-SPL9111 in the body) and efficacy in patients with advanced solid tumoursPatients with advanced solid tumoursMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-003424-76-GBStarpharma Pty Ltd33
已完成
不适用
Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitorsAdvanced/recurrent breast cancerJPRN-UMIN000004345Kyoto Prefectural University of Medicine30
进行中（未招募）
1 期
An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukemia - N/AEUCTR2004-001396-19-GBovartis Pharmaceuticals UK Ltd293